Drugs / AOC 1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05479981 | Aug 2022 → Sep 2025 | atrophic muscular disease, inherited neurodegenerative disorder, myotonic dystrophy type 1 | Avidity Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AOC 1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05479981 ↗ |
| Route | Intravenous | “AOC 1001 will be administered by intravenous (IV) infusion.” NCT05479981 ↗ |